New ALS drug data reveal a mitochondrial fix
NRG Therapeutics unpacks the molecular switch behind its ALS drug candidate, adding fresh mechanistic evidence to a trial already underway. Longevity.Technology has been following NRG5051 since the earliest days of its preclinical story, through a Parkinson’s UK partnership, a $68.1 million (£50 mil
<p>NRG Therapeutics unpacks the molecular switch behind its ALS drug candidate, adding fresh mechanistic evidence to a trial already underway. Longevity.Technology has been following NRG5051 since the earliest days of its preclinical story, through a Parkinson’s UK partnership, a $68.1 million (£50 mil</p>